XBI (XBI)

The article provides a detailed profile of the XBI ETF, focusing on its dividends, returns, and key financial statistics. It covers assets under management, dividend yield, expense ratio, and investment strategy, highlighting its exposure to US biotech stocks and equal-weighting methodology. The fund's top holdings and recent performance, along with answers to frequently asked questions, are also discussed.

The XBI ETF, managed by State Street Corporation under the SPDR brand, invests in US biotech stocks across the market-cap spectrum, with an equal-weighted portfolio emphasizing small and micro-caps. It launched on January 31, 2006, tracks the S&P Biotechnology Select Industry, and has an expense ratio of 0.35%. As of July 10, 2026, XBI has assets under management of 195.47 billion MXN and a dividend yield of 0.40%, with its last dividend amounting to 2.40 MXN.

This article provides a detailed profile of the State Street SPDR S&P Biotech ETF (XBI), outlining its dividends, returns, and key characteristics. It highlights XBI's focus on equal-weighted US biotech stocks, its management style, expense ratio, and recent performance metrics. The profile also includes information on the fund's asset allocation, geographic exposure, and top holdings.